Cargando…

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis

BACKGROUND: Natalizumab treatment provides a model for non-inflammation-induced disease progression in multiple sclerosis (MS). OBJECTIVE: To study serum contactin-1 (sCNTN1) as a novel biomarker for disease progression in natalizumab-treated relapsing-remitting MS (RRMS) patients. METHODS: Eighty-n...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Lierop, Zoë YGJ, Wieske, Luuk, Koel-Simmelink, Marleen JA, Chatterjee, Madhurima, Dekker, Iris, Leurs, Cyra E, Willemse, Eline AJ, Moraal, Bastiaan, Barkhof, Frederik, Eftimov, Filip, Uitdehaag, Bernhard MJ, Killestein, Joep, Teunissen, Charlotte E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689420/ https://www.ncbi.nlm.nih.gov/pubmed/33890520 http://dx.doi.org/10.1177/13524585211010097

Ejemplares similares

Serum Contactin-1 in CIDP: A Cross-Sectional Study
por: Wieske, Luuk, et al.
Publicado: (2021)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
por: Loonstra, Floor C., et al.
Publicado: (2022)

Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy
por: Amaador, Karima, et al.
Publicado: (2022)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?
por: Dekker, Iris, et al.
Publicado: (2019)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

Contactins in the central nervous system: role in health and disease
por: Chatterjee, Madhurima, et al.
Publicado: (2019)

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
por: Leurs, Cyra E, et al.
Publicado: (2017)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis
por: Fehmi, Janev, et al.
Publicado: (2023)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials
por: Wieske, Luuk, et al.
Publicado: (2021)

Plasma proteome in multiple sclerosis disease progression
por: Malekzadeh, Arjan, et al.
Publicado: (2019)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis
por: Dekker, Iris, et al.
Publicado: (2017)

Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis
por: Lam, KH, et al.
Publicado: (2020)

Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies
por: Chatterjee, Madhurima, et al.
Publicado: (2020)

Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis
por: Sestito, Claudia, et al.
Publicado: (2021)

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis
por: Coerver, Eline M. E., et al.
Publicado: (2022)

Blood platelet RNA enables the detection of multiple sclerosis
por: Sol, Nik, et al.
Publicado: (2020)

A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort
por: van Dam, Maureen, et al.
Publicado: (2023)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

No Evidence for Association of Autism with Rare Heterozygous Point Mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other Contactin-Associated Proteins or Contactins
por: Murdoch, John D., et al.
Publicado: (2015)

Implication of Contactins in Demyelinating Pathologies
por: Kalafatakis, Ilias, et al.
Publicado: (2021)

Perspective of patients with autoimmune diseases on COVID-19 vaccination
por: Boekel, Laura, et al.
Publicado: (2021)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype
por: Cortese, Andrea, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vac8htt38m0msnjno9871ndeds